"Infant-type hemispheric gliomas typically arise in the first year of life (range: 0–12 months) 2."
"Infant-type hemispheric gliomas belong to the family of "paediatric high-grade diffuse gliomas" of the 2021 WHO Classification of Tumours of the Central Nervous System 1. They have been recognised as a novel tumour type distinct from other paediatric high-grade gliomas, harbouring molecular mutations involving the receptor tyrosine kinases NTRK, ROS1, ALK, and MET."
"Infant-type hemispheric gliomas belong to the family of "paediatric high-grade diffuse gliomas" of the 2021 WHO Classification of Tumours of the Central Nervous System 1. They have been recognised as a novel tumour type distinct from other paediatric high-grade gliomas, harbouring molecular mutations involving the receptor tyrosine kinases NTRK, ROS1, ALK, and MET."
"GFAP: positive"
"ALK: sometimes positive in the infant-type hemispheric glioma ALK-altered"
"Infant-type hemispheric gliomas belong to the family of "paediatric high-grade diffuse gliomas" of the 2021 WHO Classification of Tumours of the Central Nervous System 1. They have been recognised as a novel tumour type distinct from other paediatric high-grade gliomas, harbouring molecular mutations involving the receptor tyrosine kinases NTRK, ROS1, ALK, and MET."
"infant-type hemispheric glioma, NTRK-altered"
"infant-type hemispheric glioma, ROS1-altered"
"infant-type hemispheric glioma, ALK-altered"
"infant-type hemispheric glioma, MET-altered"
"ALK: sometimes positive in the infant-type hemispheric glioma ALK-altered"
"diagnosis of these tumours generally requires detection of the fusion genes of tyrosine kinase NTRK1, NTRK2, NTRK3, ROS1, ALK, MET or, alternatively, a characteristic methylation profile 1-3"
"More studies are needed to evaluate the survival rate and impact of targeted therapies. Infant-type hemispheric glioma ALK-altered subtype seems to have a better 5-year survival rate than the ROS1- and NTRK-altered subtypes 2."
Expected headings
"Subtypes"
"Immunophenotype and molecular alterations"
"diagnosis of these tumours generally requires detection of the fusion genes of tyrosine kinase NTRK1, NTRK2, NTRK3, ROS1, ALK, MET or, alternatively, a characteristic methylation profile 1-3"